Cost-effectiveness of pertussis booster vaccination in the Netherlands.

Cost-effectiveness of pertussis booster vaccination in the Netherlands.

The aim of the current study is to estimate the epidemiological and economical consequences of several extended pertussis booster vaccination strategies and to explore the impact of parameters surrounded by large uncertainty on the cost-effectiveness. We developed an age structured transmission dyna...

Descripció completa

Dades bibliogràfiques
Autors principals:	Rozenbaum, M, De Cao, E, Postma, M
Format:	Journal article
Idioma:	English
Publicat:	2012

Ítems similars

Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around....
per: Rozenbaum, M, et al.
Publicat: (2012)

Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model.
per: Robin de Vries, et al.
Publicat: (2010-01-01)

An update of “Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model”
per: Tu Hong Anh T, et al.
Publicat: (2013-01-01)

Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model
per: Hak Eelko, et al.
Publicat: (2011-06-01)

Prior exposure to B. pertussis shapes the mucosal antibody response to acellular pertussis booster vaccination
per: Evi van Schuppen, et al.
Publicat: (2022-12-01)

Corrigendum to ‘Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom’
per: Pauline Versteegen, et al.
Publicat: (2021-06-01)

Age and Primary Vaccination Background Influence the Plasma Cell Response to Pertussis Booster Vaccination
per: Annieck M. Diks, et al.
Publicat: (2022-01-01)

Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis.
per: Sabine C de Greeff, et al.
Publicat: (2010-01-01)

Reemergence of Pertussis in the Highly Vaccinated Population of The Netherlands: Observations on Surveillance Data
per: Hester E. de Melker, et al.
Publicat: (2000-08-01)

Pertussis in the Netherlands: an Outbreak Despite High Levels of Immunization with Whole-Cell Vaccine
per: H.E. de Melker, et al.
Publicat: (1997-06-01)

Underreporting of the 5-year tetanus, diphtheria, pertussis and polio booster vaccination in the Danish Vaccination Register
per: Sidsel Skou Voss, et al.
Publicat: (2020-11-01)

Cost-Effectiveness of Pertussis Vaccination Schedule in Israel
per: Dean Langsam, et al.
Publicat: (2021-06-01)

Long-Term Immunogenicity upon Pertussis Booster Vaccination in Young Adults and Children in Relation to Priming Vaccinations in Infancy
per: Pauline Versteegen, et al.
Publicat: (2022-04-01)

Robust Humoral and Cellular Immune Responses to Pertussis in Adults After a First Acellular Booster Vaccination
per: Saskia van der Lee, et al.
Publicat: (2018-04-01)

Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three Countries
per: Pauline Versteegen, et al.
Publicat: (2022-05-01)

Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands
per: Joost J.M. Simons, et al.
Publicat: (2022-08-01)

Pertussis Notification Rate and Tdpa Vaccine/Booster Coverage in Adults: An Opportunity for an Epidemiological Observatory in Primary Care
per: Francesco Lapi, et al.
Publicat: (2024-09-01)

Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective?
per: Anouk T Urbanus, et al.
Publicat: (2013-01-01)

A system-view of Bordetella pertussis booster vaccine responses in adults primed with whole-cell versus acellular vaccine in infancy
per: Ricardo da Silva Antunes, et al.
Publicat: (2021-04-01)

Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters
per: da Silva Antunes, R, et al.
Publicat: (2018)

Pertussis vaccines and the role of <I>Bordetella pertussis</I> lipooligosaccharide in the immune response to pertussis infection and vaccination
per: I. A. Alekseeva, et al.
Publicat: (2021-03-01)

The Role of the Aceullular Pertussis Vaccine and the Comeback of 'Pertussis Pete'?
per: John M Conly, et al.
Publicat: (2001-01-01)

Cost-effectiveness of nonavalent HPV vaccination in the Netherlands
per: Cody Palmer, et al.
Publicat: (2024-12-01)

Pertussis toxin neutralizing antibody response after an acellular booster vaccination in Dutch and Finnish participants of different age groups
per: Aapo Knuutila, et al.
Publicat: (2022-12-01)

Safety of pertussis vaccines for adolescents
per: M. P. Kostinov, et al.
Publicat: (2020-10-01)

New features of pertussis vaccination
per: A. P. Cherdantsev, et al.
Publicat: (2020-06-01)

Insights into maternal pertussis vaccination counselling: a qualitative study on perspectives and experiences among midwives and gynaecologists in the Netherlands
per: Veja Widdershoven, et al.
Publicat: (2024-09-01)

Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.
per: Hiltsje Hepkema, et al.
Publicat: (2013-01-01)

Pertussis diagnostic practices of general practitioners in the Netherlands: A survey study
per: Jeanne Heil, et al.
Publicat: (2019-10-01)

Pertussis Toxin: A Key Component in Pertussis Vaccines?
per: Kelsey A. Gregg, et al.
Publicat: (2019-09-01)

Acellular Pertussis Vaccines and Pertussis Resurgence: Revise or Replace?
per: Clara Maria Ausiello, et al.
Publicat: (2014-07-01)

Protective Activity and Safety of Acellular Pertussis Vaccine from Vaccine and Freshly Isolated Strain Bordetella pertussis
per: E. M. Zaitsev, et al.
Publicat: (2017-04-01)

A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults
per: Geert Leroux-Roels, et al.
Publicat: (2018-01-01)

Circulation of Bordetella pertussis in the Caribbean Netherlands: a population-based seroepidemiological study
per: Maarten M. Immink, et al.
Publicat: (2021-10-01)

Systemic priming and intranasal booster with a BcfA-adjuvanted acellular pertussis vaccine generates CD4+ IL-17+ nasal tissue resident T cells and reduces B. pertussis nasal colonization
per: Kacy S. Yount, et al.
Publicat: (2023-05-01)

Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines
per: Punnee Pitisuttithum, et al.
Publicat: (2021-07-01)

Burden of early, advanced and metastatic breast cancer in The Netherlands
per: G. T. Vondeling, et al.
Publicat: (2018-03-01)

Acellular Pertussis Vaccine from Antigens of Freshly Isolated and Vaccine Strains of Bordetella pertussis with Different Genotypic Characteristics
per: E. M. Zaitsev, et al.
Publicat: (2021-09-01)

Pertussis, anti-Bordetella pertussis toxin, vaccination, and clinical surveillance
per: Amnuay Kleebayoon, et al.
Publicat: (2023-01-01)

Assays for Determining Pertussis Toxin Activity in Acellular Pertussis Vaccines
per: Kevin Markey, et al.
Publicat: (2019-07-01)